Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia SAD study of the oral tablet, ASC30, in obese ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

A gut microbe could naturally regulate sugar cravings and blood sugar levels, offering a promising alternative to drugs like Ozempic.

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor ... Apptec plans to continue expanding small molecule Phase III and commercial pipeline ...

The molecule was built using Biomea Fusion’s FUSION™ System and is designed to regenerate insulin-producing beta cells with the aim to cure diabetes. Icovamenib’s proposed mechanism of ...

epinephrine and glucagon rapidly increase the amount of active phosphorylase in pre-incubated liver slices 1,2. In order to study the nature of the change in the phosphorylase molecule ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.